dextrothyroxine has been researched along with Astrocytoma, Grade IV in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fang, S; Liu, B; Liu, Y; Sun, Q | 1 |
| Aregawi, D; Lopez, D; Scheld, WM; Schiff, D; Wick, M | 1 |
2 other study(ies) available for dextrothyroxine and Astrocytoma, Grade IV
| Article | Year |
|---|---|
Anthelmintic drug ivermectin inhibits angiogenesis, growth and survival of glioblastoma through inducing mitochondrial dysfunction and oxidative stress.
Topics: Animals; Anthelmintics; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Glioblastoma; Humans; Ivermectin; Mice; Mice, SCID; Mitochondria; Neovascularization, Pathologic; Oxidative Stress; Treatment Outcome | 2016 |
Disseminated strongyloidiasis complicating glioblastoma therapy: a case report.
Topics: Albendazole; Antiprotozoal Agents; Diffusion Magnetic Resonance Imaging; Female; Glioblastoma; Humans; Immunocompromised Host; Immunosuppressive Agents; Ivermectin; Middle Aged; Opportunistic Infections; Radiography; Strongyloidiasis | 2009 |